Phytotherapie bei Herzrhythmusstörungen

Summary

Erkrankungen des Herzens und der Blutgefäße stellen weltweit die häufigste Todesursache dar und werden oft durch Risikofaktoren wie Bluthochdruck, Arteriosklerose und Herzrhythmusstörungen verursacht. Neben der medikamentösen Standardtherapie stehen einige wirkungsvolle Phytotherapeutika zur Verfügung. Der Beitrag fasst wissenschaftliche Studien zu antiarrhythmischen Heilpflanzen zusammen. Zu ihnen gehören vor allem Ginseng, Ginkgo, Knoblauch, Eisenhut sowie Weißdorn.

Keywords

Phytotherapie - Herzrhythmusstörungen - Roter Fingerhut - Weißdorn - Crataegusextrakt WS 1442

Publikationsverlauf

Artikel online veröffentlicht:
10. Juni 2025

• Literatur

• 1 Ahn J-Y, Chu H, Leem J. et al Effectiveness and safety of traditional herbal medicine on cardiac arrhythmic condition. A systematic review and meta-analysis of randomized control clinical trial. Medicine 2024; 103: e38441
• 2 Nattel S, Harada M. Atrial remodeling and atrial fibrillation: Recent advances and translational perspectives. J Am Coll Cardiol 2014; 63 (22) 2335-2345
• 3 Schilcher H, Kammerer S, Wegener T. Leitfaden Phytotherapie. 5. Aufl. München: Elsevier, Urban & Fischer; 2021
• 4 Xing B-N, Jin S-S, Wang H. et al New diterpenoid alkaloids from Aconitum coreanum and their anti-arrhythmic effects on cardiac sodium current. Fitoterapia 2014; 94: 120-126
• 5 Hiller K, Melzig MF. Lexikon der Arzneipflanzen und Drogen. Heidelberg: Spektrum; 2003
• 6 Fatehi M, Saleh TM, Fatehi-Hassanabad Z. et al A pharmacological study on Berberis vulgaris fruit extract. J Ethnopharmacol 2005; 102 (01) 46-52
• 7 Chen B, Cai J, Song L-S. et al Effects of ginkgo biloba extract on cation currents in rat ventricular myocytes. Life Sciences 2005; 76 (10) 1111-1121
• 8 Kandiah N, Chan YF, Chen C. et al Strategies for the use of Ginkgo biloba extract, EGb 761, in the treatment and management of mild cognitive impairment in Asia: Expert consensus. CNS Neurosci Ther 2021; 27: 149-162
• 9 Peters H, Kieser M, Hölscher U.. Demonstration of the efficacy of Ginkgo biloba special extract EGb 761 on intermittent claudication – A placebo-controlled, double-blind multicenter trial. VASA 1998; 27: 108-112
• 10 Satoh H. Suppression of pacemaker activity by Ginkgo biloba extract and its main constituent, bilobalide in rat sino-atrial nodal cells. Life Sci 2005; 78 (01) 67-73
• 11 Zhao X, Yao H, Yin HL. et al Ginkgo biloba extract and ginkgolide antiarrhythmic potential by targeting hERG and ICa-L channel. J Pharmacol Sci 2013; 123 (04) 318-327
• 12 Lee CH, Kim JH. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res 2014; 38: 161-166
• 13 Yin H, Liu Z, Li F. et al Ginsenoside-Rg1 enhances angiogenesis and ameliorates ventricular remodeling in a rat model of myocardial infarction. J Molecul Med 2011; 89: 363-375
• 14 Wu W, Zhang XM, Liu PM. et al Effects of Panax notoginseng saponin Rg1 on cardiac electrophysiological properties and ventricular fibrillation threshold in dogs. Zhong Yao Li Xue Bao 1995; 16 (05) 459-463
• 15 Li C, Gao Y, Tian J. et al Sophocarpine administration preserves myocardial function from ischemia-reperfusion in rats via NF-κB inactivation. J Ethnopharmacol 2011; 135 (03) 620-625
• 16 Yang Z-F, Li C-Z, Wang W. et al Electrophysiological mechanisms of sophocarpine as a potential antiarrhythmic agent. Acta Pharmacol Sinica 2011; 32 (03) 311-320
• 17 Zhang S, Ma J-H, Zhang P-H. et al Sophocarpine attenuates the Na+-dependent Ca2+ overload induced by anemonia sulcata toxinincreased late sodium current in rabbit ventricular myocytes. J Cardiovasc Pharmacol 2012; 60 (04) 357-366
• 18 Aqel MB, Gharaibah MN, Salhab AS. Direct relaxant effects of garlic juice on smooth and cardiac muscles. J Ethnopharmacol 1991; 33 (1–2) 13-19
• 19 Ried K, Frank OR, Stocks NP. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: A randomised controlled trial. Maturitas 2010; 67 (02) 144-150
• 20 Banerjee SK, Dinda AK, Manchanda SC. et al Chronic garlic administration protects rat heart against oxidative stress induced by ischemic reperfusion injury. BMC Pharmacol 2002; 2 (01) 16
• 21 Li J, Hu D, Song X. et al The role of biologically active ingredients from natural drug treatments for arrhythmias in different mechanisms. Bio Med Res Int 2017;
• 22 Holubarsch CJF, Colucci WS, Eha J. Benefit-risk assessment of Crataegus extract WS 1442: An evidence-based review. Am J Carciovasc Drugs 2018; 18: 25-36
• 23 Petry R-J.. Die Lösung des Herzinfarkt-Problems durch g-Strophanthin. Erfahrungsheilkunde 2004; 53 (02) 65-73
• 24 Whayne Jr. TF. Clinical use of Digitalis: A state of the art review. Am J Cardiovasc Drugs 2018; 18 (06) 427-440
• 25 https://www.klein-naturarznei.de/kraeuterlexikon/strophantus.html – abgerufen am 27.04.25
• 26 Ritter M, Melichar K, Strahler S. et al Cardiac and electrophysiological effects of primary and refined extracts from Leonurus cardiaca L. (Ph. Eur.). Planta Med 2010; 76 (06) 572-582
• 27 Adams B. Geheimnisse des Herzgespannkrautes gelüftet. Pressemitteilung der Universität Leipzig; 03.08.2007. Im Internet:. https://www.uni-leipzig.de/newsdetail/artikel/geheimnisse-des-herzgespannkrautes-gelueftet-2007-08-03 Stand: 08.05.2025
• 28 Koshovyi O, Raal A, Kireyev I. et al Phytochemical and psychotropic research of Motherwort (Leonurus cardiaca L.) modified dry extracts. Plants 2021; 10: 230
• 29 Martinelli F, Perrone A, Yousefi S. et al Botanical, phytochemical, anti-microbial and pharmaceutical characteristics of Hawthorn (Crataegus monogyna Jacq.), Rosaceae. Molecules 2021; 26: 7266
• 30 Brixius K, Frank K, Münch G. et al WS 1442 (Crataegus-Extrakt) wirkt am insuffizienten menschlichen Myokard kontraktionssteigernd. Herz Kreisl 1988; 30: 28-33
• 31 Eggeling T, Regitz-Zagrosek V, Zimmermann A. et al Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure, a pooled analysis of clinical trials. Phytomed 2011; 18 (14) 1214-1219
• 32 Gündling PW.. Weißdorn – Neue Erkenntnisse zu einer alten Heilpflanze. Erfahrungsheilkunde 2017; 66 (04) 36-43
• 33 Holubarsch CJF, Colucci WS, Eha J. Benefit-risk assessment of Crataegus extract WS 1442: An evidence-based review. Am J Cardiovasc Drugs 2018; 18: 25-36
• 34 Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure. Coch Data Syst Rev 2008; 1: CD005312
• 35 Wegener T, Gündling PW, Holubarsch CJF. et al Bedeutung des Weißdornextrakts in der allgemeinen Praxis – Eine aktuelle Positionierung. MMW Fortschr Med 2018; 160: 1-7
• 36 Zorniak M, Szydlo B, Krzeminski TF. Crataegus special extract WS 1442: Up-to-date review of experimental and clinical experiences. J Physiol Pharmacol 2017; 68: 521-526
• 37 Tauchert M, Ploch M, Hübner WD.. Wirksamkeit des Weiβdorn-Extraktes LI 132 im Vergleich mit Captopril. Münch Med Wochenschr 1994; 136 (l) 27-33
• 38 Schwinger RH, Pietsch M, Frank K. et al Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 2000; 35 (05) 700-707
• 39 Wegener T. Weißdorn-Extrakt – Aktuelle Erkenntnisse zum Wirkprinzip. Phytokompass 2016; 5: 20-23
• 40 Long SR, Carey RA, Crofoot KM. et al Effect of Hawthorn (Crataegus oxycantha) crude extract and chromatographic fractions on multiple activities in a cultured cardiomyocyte assay. Phytomedicine 2006; 13: 643-650
• 41 Nabavi SF. Polyphenolic composition of Crataegus monogyna Jacq.: From chemistry to medical applications. Nutrients 2015; 7: 7708-7728
• 42 Krzeminski T, Chatterjee SS. Ischemia and early reperfusion induced arrhythmias: Beneficial effects of an extract of Crataegus oxyacantha L. Pharm Pharmacol Lett 1993; 3: 45-48
• 43 Veveris M, Koch E, Chatterjee SS. Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sci 2004; 74: 1945-1955
• 44 Zorniak M, Porc MP, Krzeminski TF. Hawthorn revisited: Time- and dose-dependent cardioprotective action of WS 1442 special extract in the reperfusion-induced arrhythmia model in rats in vivo. J Physiol Pharmacol 2019; 70: 14
• 45 Alp H, Soner BC, Baysal T. et al Protective effects of Hawthorn (Crataegus oxyacantha) extract against digoxin-induced arrhythmias in rats. Anatol J Cardiol 2015; 15: 970-975
• 46 Joseph G, Zhao Y, Klaus W. Pharmacologic action profile of crataegus extract in comparison to epinephrine, amirinone, milrinone and digoxin in the isolated perfused guinea pig heart. Arzneimittelforschung 1995; 45: 1261-1265
• 47 Müller A, Linke W, Klaus W.. Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes. Planta Med 1999; 65: 335-339
• 48 Pöpping S, Rose H, Ionescu I. et al Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes. Arzneimittelforschung 1995; 45: 1157-1161
• 49 Rieckeheer E, Schwinger RH, Bloch W. et al Hawthorn special extract WS 1442 increases red blood cell NO-formation without altering red blood cell deformability. Phytomedicine 2011; 19: 20-24
• 50 Hu YF, Chen YJ, Lin YJ. et al Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 2015; 12: 230-243
• 51 Van Wagoner DR.. Oxidative stress and inflammation in atrial fibrillation: Role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008; 52: 306-313
• 52 Koller M. Weißdorn-Spezialextrakt in der Therapie früher Stadien der KHK-assoziierten Herzinsuffizienz. Ergebnisse einer prospektiven Kohortenstudie zur Wirtschaftlichkeit und zum Einfluss auf die Lebensqualität der Patienten. MMW Fortschr Med 2005; 147: 159-164
• 53 Holubarsch CJF, Colucci WS, Meinertz T. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: The SPICE trial. Eur J Heart Fail 2008; 10: 1255-1263
• 54 Wyss C, Gündling PW, Kostev K.. Real world effectiveness of Hawthorn special extract WS 1442 in a retrospective cohort study from Germany. Sci Rep 2024; 14 (01) 22986
• 55 Weglicki W, Quamme G, Tucker K. et al Potassium, magnesium, and electrolyte imbalance and complications in disease management. Clin Exp Hypertens 2005; 27: 95-112
• 56 Naveed M, Wenhua L, Gang W. et al A novel ventricular restraint device (ASD) repetitively deliver Salvia miltiorrhiza to epicardium have good curative effects in heart failure management. Biomed Pharmacother 2017; 95: 701-710
• 57 Tauchert M, Gildor A, Lipinski J. Einsatz des hochdosierten Crataegusextraktes WS 1442 in der Therapie der Herzinsuffizienz Stadium NYHA II. Herz 1999; 24: 465-474
• 58 Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class III heart failure. Am Heart J 2002; 143: 910-915
• 59 Zick SM, Vautaw BM, Gillespie B. et al Hawthorn extract randomized blinded chronic heart failure (HERBCHF) trial. Eur J Heart Fail 2009; 11: 990-999